Newsroom

back

2016-12-20

Imatinib Accord Launch

Accord Healthcare launches Imatinib Accord 100 mg and 400 mg in the UK.

Accord Healthcare launches Imatinib Accord[1] in the UK, a tyrosine-kinase inhibitor indicated for the treatment of:

  • Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
  • Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
  • Adult patients with Ph+ CML in blast crisis.
  • Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
  • Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

Imatinib Accord is available in film-coated tablets of 100 mg and 400 mg in packs of 60 and 30 tablets respectively with dose colours highlighted to help reduce the risk of dispensing errors. The product is packed in cross-perforated blisters allowing for individual products to be removed from the main body of the blister without compromising the product, becoming more convenient for patients and hospital staff.

Imatinib Accord launch will bring a more affordable treatment option for patients, contributing to healthcare cost containment.

[1]Imatinib Accord is currently not indicated for the treatment of gastrointestinal stromal tumours. It should not be prescribed and/or delivered for this indication. In addition, drug substitution is not allowed for this indication.

back